# Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation

Study · id `cardio:ct-nct02475642` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02475642](<https://clinicaltrials.gov/study/NCT02475642>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02475642

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 152 participants.

## Technical summary

Registry record NCT02475642. Randomized; no masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2016-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 152 participants (enrolled count; ClinicalTrials.gov record NCT02475642, source copy `cardio:ctgov-nct02475642-2016-04-28`, retrieved 2026-10-26)
- Start date: 2014-03 (registry gives no type) (ClinicalTrials.gov record NCT02475642, source copy `cardio:ctgov-nct02475642-2016-04-28`, retrieved 2026-10-26)
- Primary completion: 2016-08 (anticipated) (ClinicalTrials.gov record NCT02475642, source copy `cardio:ctgov-nct02475642-2016-04-28`, retrieved 2026-10-26)
- Completion: 2016-08 (anticipated) (ClinicalTrials.gov record NCT02475642, source copy `cardio:ctgov-nct02475642-2016-04-28`, retrieved 2026-10-26)
- Countries: Belgium (ClinicalTrials.gov record NCT02475642, source copy `cardio:ctgov-nct02475642-2016-04-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02475642-2016-04-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation
- Acronym: POWDER-AF
- Condition: Atrial Fibrillation
- Intervention (Other): PVI-ADT
- Intervention (Other): PVI+ADT
- Lead sponsor: VZW Cardiovascular Research Center Aalst
- Lead sponsor class: OTHER
- Collaborator: AZ Sint-Jan AV
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as a collaborator: AZ Sint-Jan AV (`cardio:org-az-sint-jan-av`)

## Provenance

Content hash: b353e0130e8926eb059f03a116e6c8b7f4cd4348a8d00b210a1c716197c3a511
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
